Clinical trialNCT01372579UnknownPhase 2Interventional

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

SponsorNorthwestern UniversityEnrollment30Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast CancerProgesterone Receptor-negative Breast CancerStage IA Breast CancerStage IB Breast Cancer+5 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Virginia Kaklamani, MD
Northwestern University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Northwestern University
Chicago, Illinois, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Aug 2011
Primary completion: 30 Jun 2020
Completion: 30 Jun 2021
Last update posted: 7 Jun 2019
Registered enrollment: 30
Registry id: NCT01372579

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.